Welcome to our dedicated page for YIELD10 BISCIENCE NEW news (Ticker: YTEN), a resource for investors and traders seeking the latest updates and insights on YIELD10 BISCIENCE NEW stock.
Yield10 Bioscience, Inc. (Nasdaq: YTEN) is a pioneering agricultural bioscience company focusing on the development of cutting-edge technologies for significant improvements in crop yield within the United States and Canada. Founded in 1992 and headquartered in Woburn, Massachusetts, Yield10 leverages advanced genetic engineering to develop high-value traits in seeds, targeting the agriculture and food industries through its Trait Factory. The company has a dedicated oilseed development center in Saskatchewan, Canada.
The core mission of Yield10 is to harness the genetic potential of the oilseed Camelina sativa ('Camelina') for the production of sustainable seed products. These products include feedstock oils for renewable diesel and sustainable aviation biofuels, omega-3 (EPA and DHA+EPA) oils for pharmaceutical, nutraceutical, and aquafeed applications, and future plans for PHA biomaterials to be used as biodegradable bioplastics.
Yield10’s research initiatives are bolstered by strategic partnerships with industry giants such as Bayer AG for soybean traits, Forage Genetics International, LLC for forage sorghum traits, J. R. Simplot Company for potato traits, and GDM Seeds Inc. for evaluating yield traits in soybeans. These collaborations underscore the company’s commitment to innovation and broadening the impact of its technologies.
Significant recent milestones include the development and successful field testing of proprietary winter Camelina varieties engineered for herbicide tolerance. These varieties showed promising results in tolerating glufosinate and Group 2 herbicides, which are crucial for managing weeds and ensuring high yield in crop rotations across North America. This advancement is expected to facilitate the large-scale adoption of Camelina for biofuel and omega-3 oil markets, with the potential for commercial production as early as 2025.
Regulatory progress has been a key aspect of Yield10’s strategy, with USDA-APHIS determining that its genetically engineered Camelina traits are not subject to certain regulations, allowing for expanded planting and breeding in the United States. Additionally, the Canadian Food Inspection Agency has cleared Yield10's E3902 Camelina, which features enhanced oil production and a lighter seed coat.
Yield10 continues to build on its commercial and regulatory achievements, exemplified by the recent agreement with Vision Bioenergy Oilseeds to license Camelina varieties for biofuel feedstock production. This collaboration aims to support the growing demand for low-carbon intensity feedstock oil, aligning with global decarbonization goals.
For more detailed information about Yield10 Bioscience and its innovative endeavors, visit www.yield10bio.com or follow the company on X (formerly Twitter), Facebook, and LinkedIn.
Yield10 Bioscience (Nasdaq: YTEN) has initiated an underwritten public offering of its common stock, with terms subject to market conditions. The offering is made under an effective shelf registration statement filed with the SEC. Maxim Group LLC serves as the sole book-running manager for this offering. Yield10 focuses on agricultural biosciences, developing crop innovations aimed at enhancing food security and sustainability through its unique gene discovery platform.
Yield10 Bioscience (Nasdaq:YTEN) has announced successful field tests of its Camelina sativa lines engineered to produce PHA bioplastics directly in seeds. This innovative approach could lower production costs and drive large-scale adoption in the plastics market. Testing showed PHA levels in mature seeds reached up to 6%. The company aims to scale testing in 2021 and is targeting a PHA content of 5-20% of mature seed weight for commercial applications. This milestone aligns with global trends towards sustainable agriculture and low-carbon products.
Yield10 Bioscience (Nasdaq:YTEN) announced that Meghna Malik, Ph.D., will present at the virtual 4th CRISPR AgBio Congress on December 2, 2020. Her presentation, focusing on increasing seed yield and oil content in Camelina using CRISPR, will highlight a five percent increase in oil production per plant. Dr. Malik will also join a roundtable discussion on next-generation agricultural traits. Yield10 aims to enhance crop yields through innovative genome editing techniques, with future plans for further research and collaborations in 2021.
Yield10 Bioscience (Nasdaq: YTEN) reported its financial results for Q3 2020, showing a net loss of $2.2 million or $0.87 per share, compared to a loss of $2.0 million or $6.33 per share in Q3 2019. The company raised $5.7 million through a public offering and private placement, enriching its balance sheet. Key advancements include collaborations with Rothamsted Research for omega-3 oil production in Camelina, and ongoing field tests to evaluate new traits in Camelina and canola. Despite challenges from COVID-19, Yield10 aims to generate proof points for its traits by early 2021.
Yield10 Bioscience (Nasdaq: YTEN) has entered into a collaboration agreement with Rothamsted Research to advance the development of omega-3 oils in Camelina sativa. This partnership aims to leverage Rothamsted's expertise to create sustainable, plant-based omega-3 oils that mimic fish oil, essential for aquaculture and human health. The agreement includes a two-year exclusive option for Yield10 to license the omega-3 technology. Rothamsted's research has successfully demonstrated the production of these oils, setting the stage for commercial viability.
Yield10 Bioscience, Inc. (NASDAQ: YTEN) announced it will report its Q3 2020 financial results and corporate update on November 12, 2020. The management will hold a conference call at 4:30 p.m. ET to discuss the results and provide highlights, followed by a Q&A session. Interested parties can access the call via phone or live webcast. Yield10 focuses on crop innovations to improve yield and sustainability, utilizing its GRAIN gene discovery platform and partnering with agricultural firms. The company is headquartered in Woburn, MA.
Yield10 Bioscience (Nasdaq:YTEN) has initiated field testing of winter Camelina sativa varieties to assess their emergence and agronomic performance for commercial cover crop use in North America. This testing follows prior evaluations in the 2019/2020 season, aiming to establish seed and oil yield potential while scaling up specific plant lines. The company plans to generate data from different geographic locations, enhancing the development of Camelina varieties with proprietary traits for wider agricultural applications.
Yield10 Bioscience (NASDAQ: YTEN) will present at the H.C. Wainwright 22nd Annual Global Investment Conference from September 14-16, 2020. CEO Oliver Peoples will discuss the company's business strategy on September 14 at 11:00 am ET and will also participate in one-on-one investor meetings. Yield10 focuses on agricultural innovations, employing tools like the GRAIN gene discovery system, and aims to commercialize new traits for crops such as canola and soybean. The company is headquartered in Woburn, MA, with a center in Saskatoon, Canada.
Yield10 Bioscience will present at the LD 500 Virtual Conference on September 2, 2020, at 1:20 pm ET. CEO Oliver Peoples, Ph.D., will lead the presentation and participate in a live Q&A session. The conference runs from September 1-4, 2020, allowing for one-on-one meetings with attendees. Yield10 focuses on developing crop innovations to enhance global food security by utilizing tools like the GRAIN gene discovery tool and Fast Field Testing for Camelina oilseed. For more details, visit their website.
Yield10 Bioscience (Nasdaq: YTEN) announced the closing of an underwritten public offering of 835,000 shares at $4.25 each, generating gross proceeds of approximately $4.0 million. Maxim Group LLC exercised an over-allotment option for an additional 116,835 shares. Concurrently, existing investor Jack W. Schuler's affiliates purchased 396,450 shares in a private placement for around $1.7 million. The offering was executed under an effective shelf registration filed with the SEC. Proceeds will support Yield10's innovations in sustainable agriculture.
FAQ
What is the current stock price of YIELD10 BISCIENCE NEW (YTEN)?
What is the market cap of YIELD10 BISCIENCE NEW (YTEN)?
What does Yield10 Bioscience do?
Where is Yield10 Bioscience headquartered?
What are some recent achievements of Yield10 Bioscience?
Who are Yield10 Bioscience’s key partners?
What is Camelina sativa?
What is the significance of Yield10’s herbicide tolerance tests?
What are Yield10’s future plans for Camelina?
What regulatory milestones has Yield10 achieved?
How is Yield10 addressing the demand for omega-3 oils?
Where can I find more information about Yield10 Bioscience?
